Suchergebnisse - "Breccia, Massimo"

PubPharm (131)

1

Pharmacotherapeutic advances for chronic myelogenous leukemia : beyond tyrosine kinase inhibitors

enthalten in: Expert opinion on pharmacotherapy | 2024

von Costa, A. | Scalzulli, E. | Carmosino, I. | +4

2

How to improve treatment-free remission eligibility in chronic myeloid leukaemia?

enthalten in: British journal of haematology | 2024

von Costa, A. | Breccia, M.

3

The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib

enthalten in: Annals of hematology | 2024

von Mulas, O. | Abruzzese, E. | Luciano, L. | +26

4

Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice

enthalten in: Leukemia & lymphoma | 2023

von Ielo, C. | Scalzulli, E. | Carmosino, I. | +4

5

One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission

enthalten in: European journal of haematology | 2023

von Laganà, A. | Pepe, S. | Scalzulli, E. | +8

6

Interferon in chronic myeloid leukaemia : Is it useful for treatment-free remission?

enthalten in: British journal of haematology | 2023

von Breccia, M. | Saglio, G.

7

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia : A study from the Registro Italiano LMC and Campus CML

enthalten in: Cancer | 2023

von Tiribelli, M. | Latagliata, R. | Breccia, M. | +38

8

Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials

enthalten in: Annals of hematology | 2023

von Luciano, L. | Latagliata, R. | Gugliotta, G. | +18

9

Management of Chronic Myeloid Leukemia Patients in Later Lines : The Role of Ponatinib and New Compounds

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Scalzulli, E. | Carmosino, I. | Costa, A. | +3

10

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs : 4-year phase 1 safety and efficacy results

enthalten in: Leukemia | 2023

von Mauro, M. | Hughes, T. | Kim, D. | +23

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[14]